CN111423510B - 重组抗人pd-1抗体及其应用 - Google Patents

重组抗人pd-1抗体及其应用 Download PDF

Info

Publication number
CN111423510B
CN111423510B CN201910022548.9A CN201910022548A CN111423510B CN 111423510 B CN111423510 B CN 111423510B CN 201910022548 A CN201910022548 A CN 201910022548A CN 111423510 B CN111423510 B CN 111423510B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
fragment
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910022548.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111423510A (zh
Inventor
张锦超
王荣娟
焦莎莎
王双
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Konuoxincheng Technology Co ltd
Maiwei Shanghai Biotechnology Co ltd
Original Assignee
Beijing Konuoxincheng Technology Co ltd
Maiwei Shanghai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Konuoxincheng Technology Co ltd, Maiwei Shanghai Biotechnology Co ltd filed Critical Beijing Konuoxincheng Technology Co ltd
Priority to CN201910022548.9A priority Critical patent/CN111423510B/zh
Priority to TW109100705A priority patent/TW202043271A/zh
Priority to US17/422,123 priority patent/US20230104769A1/en
Priority to KR1020217024728A priority patent/KR20210113635A/ko
Priority to PCT/CN2020/071353 priority patent/WO2020143749A1/zh
Priority to JP2021540076A priority patent/JP2022517216A/ja
Priority to CA3126302A priority patent/CA3126302A1/en
Priority to EP20738344.9A priority patent/EP3919514A4/en
Publication of CN111423510A publication Critical patent/CN111423510A/zh
Application granted granted Critical
Publication of CN111423510B publication Critical patent/CN111423510B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910022548.9A 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用 Active CN111423510B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201910022548.9A CN111423510B (zh) 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用
TW109100705A TW202043271A (zh) 2019-01-10 2020-01-09 重組抗人程序性細胞死亡蛋白1抗體及其應用
KR1020217024728A KR20210113635A (ko) 2019-01-10 2020-01-10 재조합 항인간 pd-1 항체 및 이의 적용
PCT/CN2020/071353 WO2020143749A1 (zh) 2019-01-10 2020-01-10 重组抗人pd-1抗体及其应用
US17/422,123 US20230104769A1 (en) 2019-01-10 2020-01-10 Recombinant anti-human pd-1 antibody and application thereof
JP2021540076A JP2022517216A (ja) 2019-01-10 2020-01-10 組換え抗ヒトpd-1抗体およびその用途
CA3126302A CA3126302A1 (en) 2019-01-10 2020-01-10 Recombinant anti-human pd-1 antibody and application thereof
EP20738344.9A EP3919514A4 (en) 2019-01-10 2020-01-10 RECOMBINANT ANTI-HUMAN PD-1 ANTIBODY AND USE THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910022548.9A CN111423510B (zh) 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用

Publications (2)

Publication Number Publication Date
CN111423510A CN111423510A (zh) 2020-07-17
CN111423510B true CN111423510B (zh) 2024-02-06

Family

ID=71521975

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910022548.9A Active CN111423510B (zh) 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用

Country Status (8)

Country Link
US (1) US20230104769A1 (cg-RX-API-DMAC7.html)
EP (1) EP3919514A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022517216A (cg-RX-API-DMAC7.html)
KR (1) KR20210113635A (cg-RX-API-DMAC7.html)
CN (1) CN111423510B (cg-RX-API-DMAC7.html)
CA (1) CA3126302A1 (cg-RX-API-DMAC7.html)
TW (1) TW202043271A (cg-RX-API-DMAC7.html)
WO (1) WO2020143749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
US20250270320A1 (en) * 2020-12-10 2025-08-28 Eutilex Co., Ltd. Anti-pd-1 antibody and uses thereof
CN114907478A (zh) * 2021-02-08 2022-08-16 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
WO2025102227A1 (zh) * 2023-11-14 2025-05-22 成都盛世君联生物技术有限公司 一种抗pd-1抗体及其生物材料和产品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN108218988A (zh) * 2017-11-29 2018-06-29 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN108727504A (zh) * 2018-04-16 2018-11-02 中国科学院生物物理研究所 一种ifn与抗pd-l1抗体的融合蛋白及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
CN106632674B (zh) * 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN106699889A (zh) * 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
CN109152798B (zh) * 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
CN107446048B (zh) * 2017-09-13 2021-03-30 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
KR20220114063A (ko) * 2019-12-13 2022-08-17 큐진 인크. 신규한 인터루킨-15 (il-15) 융합 단백질 및 이의 용도
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN108218988A (zh) * 2017-11-29 2018-06-29 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN108727504A (zh) * 2018-04-16 2018-11-02 中国科学院生物物理研究所 一种ifn与抗pd-l1抗体的融合蛋白及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies;George K. Philips;International Immunology;第27卷(第1期);39–46 *
抗PD - 1 /PD - L1 单抗的免疫相关不良反应;闫晨霞;华西药学杂志;第33卷(第3期);333-336 *

Also Published As

Publication number Publication date
JP2022517216A (ja) 2022-03-07
KR20210113635A (ko) 2021-09-16
EP3919514A4 (en) 2022-12-07
TW202043271A (zh) 2020-12-01
WO2020143749A1 (zh) 2020-07-16
CA3126302A1 (en) 2020-07-16
US20230104769A1 (en) 2023-04-06
EP3919514A1 (en) 2021-12-08
CN111423510A (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
AU2020273695B2 (en) Antibody against claudin 18A2 and use thereof
JP7513605B2 (ja) 新規な抗体ならびにそれを調製および使用するための方法
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
TWI859319B (zh) 抗cd73抗體及組合物
JP6518005B2 (ja) Pd−l1抗体
JP2020532965A (ja) 抗cd137分子及びその使用
US20210363266A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
AU2017305366A1 (en) Anti-PD-L1 nanobody and use thereof
JP2022514693A (ja) Muc18に特異的な抗体
TWI832013B (zh) 一種抗pd-l1抗原結合蛋白及其應用
EP3919514A1 (en) Recombinant anti-human pd-1 antibody and application thereof
WO2022100590A1 (zh) 针对密蛋白18a2的adcc增强型人源化抗体及其应用
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
JP2026510747A (ja) Pd-1/pvrig/tigit結合タンパク質を含む医薬組成物及びその医薬的使用
CN121079322A (zh) 抗cd27单克隆抗体及其应用
AU2022324406A1 (en) Anti-cd79b×cd3 bispecific antibody and use thereof
RU2811431C2 (ru) Антитело против клаудина 18a2 и его применение
CN113929781A (zh) 抗pd-1抗体及其稳定制剂
HK40062048A (en) Antibody against claudin 18a2 and use thereof
HK40062048B (en) Antibody against claudin 18a2 and use thereof
HK40017675A (en) Epcam-targeting antibody and preparation and application thereof
HK40017675B (en) Epcam-targeting antibody and preparation and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 105, building 2, No. 230, Cailun Road, Pudong New Area, Shanghai, 201210

Applicant after: Maiwei (Shanghai) Biotechnology Co.,Ltd.

Applicant after: Beijing konuoxincheng Technology Co.,Ltd.

Address before: 201210 room 105, building 2, no.230, Cailun Road, No.86 Faraday Road, Shanghai pilot Free Trade Zone

Applicant before: MABWELL (SHANGHAI) BIOSCIENCE Co.,Ltd.

Applicant before: Beijing konuoxincheng Technology Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant